Jim Cramer on Biotech and Presidential Politics

TheStreet's Action Alerts PLUS Portfolio Manager Jim Cramer said the negative rhetoric about the biotech space will subside as Democratic presidential hopeful Bernie Sanders loses momentum. 'The drug companies have a window to go higher, including biotech,' Cramer said, adding that the rise of Valeant Pharmaceuticals (VRX) is moving up the entire group. For more biotech analysis, Cramer points to TheStreet's Biotech Bible.

At the time of publication, Jim Cramer's charitable trust Action Alerts PLUS held no positions in stocks mentioned.